FDA approves oral treatment for opioid-induced constipation

The FDA has approved the oral treatment for opioid-induced constipation naloxegol (Movantik), according to a Gastroenterology & Endoscopy News report.

Advertisement
Carrie Pallardy

Movantik is designed for adults with chronic non-cancer pain. The drug is a peripherally acting mu-opiod-receptor antagonist used to decrease the constipation side effect of opioids, according to the report.

More articles on gastroenterology:
19 things to know about GI compensation & satisfaction in 2014
AGA releases new tool for Crohn’s disease treatment
How has the Obama presidency affected the field of GI?

A smarter way to evaluate pharmacy staffing strategy

Recommended Live Webinar on Apr 6, 2026 11:00 AM - 12:00 PM CDT

Advertisement

Next Up in GI & Endoscopy

  • 5 female gastroenterologists to know

    While gastroenterology has historically been a male-dominated specialty, a growing number of women are driving innovation across clinical care, research…

    By: Sophie Eydis

  • 5 studies scaring gastroenterologists 

    Gastroenterologists face rising clinical and operational obstacles as the GI diseases become more prevalent in the U.S. population and reimbursement…

    By: Francesca Mathewes
Advertisement

Comments are closed.